The nanoparticles, utilizing an enhanced permeability and retention effect to highly accumulate inside tumors, provide an immunogenic milieu in TME and a systemic tumor-specific immune response for the ensuing intraperitoneal injection of PD-L1 antibody, amplifying its antitumor efficacy [147]. The gene discussed is CD274; the disease is neoplasm.